STRATEC WITH FURTHER ACCELERATION IN SALES AND EARNINGS GROWTH IN FIRST QUARTER OF 2021 - Sales up by 32.5% at constant currency to € 72.0 million in Q1/2021; nominal +27.4%   (Q1/2020: € 56.5 million) - Adjusted EBIT in Q1/2021 rises by 109.5% to € 16.0 million (Q1/2020: € 7.7 million) - Adjusted EBIT margin for Q1/2021 improves by 870 basis po [ … ]

STRATEC WITH DOUBLE-DIGIT SALES GROWTH AND SIGNIFICANTLY INCREASED PROFITABILITY IN 2020 - Consolidated sales at constant currency up by 18.4% to € 250.1 million in 2020;  nominal: +16.8% (2019: € 214.2 million) - Adjusted EBIT in 2020 increases by 42.6% to € 41.7 million (2019: € 29.3 million) - Adjusted EBIT margin in 2020 improves by 300 basi [ … ]

STRATEC SE APPOINTS NEW SUPERVISORY BOARD CHAIR Birkenfeld, November 26, 2020 At its meeting today, the Supervisory Board of STRATEC SE elected Prof. Dr. Stefanie Remmele as the new Chairwoman of the Supervisory Board as of November 26, 2020. Prof. Dr. Remmele is Professor of Medical Technology at Landshut University of Applied Sciences and has b [ … ]

STRATEC WITH DOUBLE-DIGIT GROWTH IN SALES AND EARNINGS IN FIRST NINE MONTHS OF 2020 - Sales in 9M/2020 rise year-on-year by 13.1% to € 179.1 million (9M/2019: € 158.3 million) - Adjusted EBIT in 9M/2020 up 40.7% to € 28.1 million (9M/2019: € 20.0 million) - Adjusted EBIT margin improves year-on-year by 310 basis points to 15.7% - Well-filled devel [ … ]

STRATEC WITH SIGNIFICANT SALES GROWTH AND INCREASED PROFITABILITY IN THE FIRST HALF OF 2020 - 2020 financial guidance amended to account for COVID-19 pandemic: Organic sales growth of 14.0% to 18.0% and adjusted EBIT margin of around 15.5% to 16.5% expected - COVID-19 pandemic leads to substantial additional demand for in-vitro diagnostics solutio [ … ]